202 related articles for article (PubMed ID: 24569963)
1. Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation.
Puppin C; Durante C; Sponziello M; Verrienti A; Pecce V; Lavarone E; Baldan F; Campese AF; Boichard A; Lacroix L; Russo D; Filetti S; Damante G
Endocrine; 2014 Nov; 47(2):528-36. PubMed ID: 24569963
[TBL] [Abstract][Full Text] [Related]
2. High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.
Simbolo M; Mian C; Barollo S; Fassan M; Mafficini A; Neves D; Scardoni M; Pennelli G; Rugge M; Pelizzo MR; Cavedon E; Fugazzola L; Scarpa A
Virchows Arch; 2014 Jul; 465(1):73-8. PubMed ID: 24828033
[TBL] [Abstract][Full Text] [Related]
3. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
[TBL] [Abstract][Full Text] [Related]
4. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
[TBL] [Abstract][Full Text] [Related]
5. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
6. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Moura MM; Cavaco BM; Pinto AE; Leite V
J Clin Endocrinol Metab; 2011 May; 96(5):E863-8. PubMed ID: 21325462
[TBL] [Abstract][Full Text] [Related]
8. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.
Agrawal N; Jiao Y; Sausen M; Leary R; Bettegowda C; Roberts NJ; Bhan S; Ho AS; Khan Z; Bishop J; Westra WH; Wood LD; Hruban RH; Tufano RP; Robinson B; Dralle H; Toledo SP; Toledo RA; Morris LG; Ghossein RA; Fagin JA; Chan TA; Velculescu VE; Vogelstein B; Kinzler KW; Papadopoulos N; Nelkin BD; Ball DW
J Clin Endocrinol Metab; 2013 Feb; 98(2):E364-9. PubMed ID: 23264394
[TBL] [Abstract][Full Text] [Related]
9. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
10. RAS proto-oncogene in medullary thyroid carcinoma.
Moura MM; Cavaco BM; Leite V
Endocr Relat Cancer; 2015 Oct; 22(5):R235-52. PubMed ID: 26285815
[TBL] [Abstract][Full Text] [Related]
11. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
[TBL] [Abstract][Full Text] [Related]
12. CGH alterations in medullary thyroid carcinomas in relation to the RET M918T mutation and clinical outcome.
Frisk T; Zedenius J; Lundberg J; Wallin G; Kytölä S; Larsson C
Int J Oncol; 2001 Jun; 18(6):1219-25. PubMed ID: 11351254
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
[TBL] [Abstract][Full Text] [Related]
14. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor-kappaB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma.
Gallel P; Pallares J; Dolcet X; Llobet D; Eritja N; Santacana M; Yeramian A; Palomar-Asenjo V; Lagarda H; Mauricio D; Encinas M; Matias-Guiu X
Hum Pathol; 2008 Jul; 39(7):994-1001. PubMed ID: 18508109
[TBL] [Abstract][Full Text] [Related]
16. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.
Marsh DJ; Learoyd DL; Andrew SD; Krishnan L; Pojer R; Richardson AL; Delbridge L; Eng C; Robinson BG
Clin Endocrinol (Oxf); 1996 Mar; 44(3):249-57. PubMed ID: 8729519
[TBL] [Abstract][Full Text] [Related]
17. Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations.
Chang TC; Wu SL; Hsiao YL
Acta Cytol; 2005; 49(5):477-82. PubMed ID: 16334022
[TBL] [Abstract][Full Text] [Related]
18. Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma.
Censi S; Galuppini F; Clausi C; Battheu F; Manso J; Piva I; Corvaglia S; Pedron MC; Mondin A; Iacobone M; Torresan F; Merante Boschin I; Bertazza L; Barollo S; Pennelli G; Mian C
Thyroid; 2024 Feb; 34(2):177-185. PubMed ID: 38047536
[No Abstract] [Full Text] [Related]
19. Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.
Rapa I; Saggiorato E; Giachino D; Palestini N; Orlandi F; Papotti M; Volante M
J Clin Endocrinol Metab; 2011 Jul; 96(7):2146-53. PubMed ID: 21543427
[TBL] [Abstract][Full Text] [Related]
20. CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis.
Cordero-Barreal A; Caleiras E; López de Maturana E; Monteagudo M; Martínez-Montes ÁM; Letón R; Gil E; Álvarez-Escolá C; Regojo RM; Andía V; Marazuela M; Guadalix S; Calatayud M; Robles-Díaz L; Aguirre M; Cano JM; Díaz JÁ; Saavedra P; Lamas C; Azriel S; Sastre J; Aller J; Leandro-García LJ; Calsina B; Roldán-Romero JM; Santos M; Lanillos J; Cascón A; Rodríguez-Antona C; Robledo M; Montero-Conde C
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32791518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
